Can a heart drug tame rheumatoid arthritis?

NCT ID NCT07730723

Not yet recruiting Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests whether nicorandil, a drug currently used for heart conditions, can reduce disease activity and symptoms in people with rheumatoid arthritis. About 70 adults with moderate-to-severe RA will take either nicorandil or a placebo twice daily for three months, while continuing their usual arthritis medications. Researchers will track changes in joint inflammation, painkiller use, and daily function to see if nicorandil offers added benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nicorandil, a drug that opens potassium channels in blood vessels, taken as an oral tablet
What this could lead to: If it works, nicorandil could offer a new treatment option to help control rheumatoid arthritis symptoms and improve daily function.
What could go wrong: This is an early-to-mid-stage trial with only 70 participants, so results may not apply broadly. Nicorandil can cause side effects like headache, dizziness, or nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease Inflammation rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS (RA)

Contacts and locations

Locations

Ain Shams University

Cairo, Abbasia, 11566, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.